Frontlight ResearchEarly access
Trial site
Korea Cancer Center Hospital
- 8running trials
- 3closed trials
The trials here
What the 11 trials at this site are about, from their registry records.
- Conditions
- Ovarian cancer5 trials
- Cervical cancer2 trials
- Sarcoma2 trials
- Childhood cancers1 trial
- Endometrial cancer1 trial
- Head and neck cancer1 trial
- Metastatic breast cancer1 trial
- Triple-negative breast cancer1 trial
- Phase
- Phase 37 trials
- Phase 2/32 trials
- Phase 1/21 trial
- Status
- Active, not recruiting7 trials
- Completed3 trials
- Recruiting1 trial
- Lead sponsor
- National Cancer Institute (NCI)3 trials
- AstraZeneca1 trial
- GOG Foundation1 trial
- Inhibrx Biosciences, Inc1 trial
- MedPacto, Inc.1 trial
- and 4 more
Running trials
Recruiting
Recruiting
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Childhood cancers1 recruiting
- Sarcoma1 recruiting
Closed trials
Completed
Completed
Completed
Site data: ClinicalTrials.govUpdated 14 Nov 2026